Crossmark

Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?

Crossref DOI link: https://doi.org/10.1007/s10096-023-04732-4

Published Online: 2023-12-14

Published Print: 2024-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Le Terrier, Christophe https://orcid.org/0000-0002-5455-5576
Freire, Samanta

Nordmann, Patrice https://orcid.org/0000-0002-1343-1622
Poirel, Laurent https://orcid.org/0000-0001-5160-5286
Funding

Funding for this research was provided by:

University of Fribourg
License Information

Text and Data Mining valid from 2023-12-14

Version of Record valid from 2023-12-14
More Information

Article History

Received: 24 October 2023

Accepted: 29 November 2023

First Online: 14 December 2023

Declarations

:

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below